Healios KK

Healios announced on the 19th that a patent has been registered in China for its next-generation iPS cell, the Universal Donor Cell, or UDC, created using gene-editing technology. The UDC is a low-immunogenic iPS cell made by removing polymorphic HLA through gene editing and introducing HLA-G, PD-L1, and PD-L2, giving it resistance to both adaptive and innate immunity. A suicide gene has also been introduced as a safety switch, and the company says the UDC is expected to serve as a next-generation technology platform for creating regenerative medicine products as a raw material for transplanted cells.